Cancer patients exhibited significantly lower serum levels of irisin compared to controls (2.47 ± 0.57 and 3.24 ± 0.66 μg/ml, respectively, p < 0.001) (Fig. 1). This evidence concerns the gene FNDC5 and cancer.